Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Renub Research | PRODUCT CODE: 1498419

Cover Image

PUBLISHER: Renub Research | PRODUCT CODE: 1498419

Global Molecular Diagnostics Market Report by Technology (Chips and Microarrays, In Situ Hybridization, Sequencing, Mass Spectrometry, PCR, Other Technologies) Application Product End Users Countries and Company Analysis 2024-2032

PUBLISHED:
PAGES: 240 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Excel (Dashboard)
USD 2290
PDF (Single User License)
USD 2790
PDF (5 User License + Excel)
USD 3290
PDF (Corporate License)
USD 3790

Add to Cart

The Global Molecular Diagnostics Market size will surpass US$ 26.27 billion by 2032 from US$ 11.88 billion in 2023, with a CAGR of 9.21% from 2024 to 2032.

Molecular diagnostics involves identifying genomic variants to aid in detecting, diagnosing, sub-classifying, prognosis, and monitoring therapy response. It utilizes techniques to analyze biological markers in the genome and proteome, examining how cells express genes as proteins. This field applies molecular biology to medical testing. It is widely used for identifying biological markers in the genome and proteome, such as detecting bacterial genes using PCR-based techniques and measuring expressed bacterial infection-specific proteins using enzyme-linked immunosorbent assay (ELISA) and proteomics.

The growing global geriatric population and the prevalence of diseases like cancer, cardiovascular diseases, neurological disorders, diabetes, obesity, and infectious diseases are driving market growth. The World Bank Group data indicates that 2022 there were approximately 779 million people aged 65 years and above globally. Furthermore, the no. of individuals aged 80 years and above is projected to double by 2050, surpassing more than 1.5 billion. This trend is expected to have a significant impact on the market. Additionally, the market is expected to experience growth due to the rising incidence of infectious diseases.

The potential market expansion is due to an increase in diseases such as HIV, HPV, and STI, as well as initiatives by significant market players to improve access to cost-effective resources. It also mentions that infections are expected to drive growth in the molecular diagnostics market and highlights the importance of molecular tests in disease diagnostics despite their high cost. The increasing global incidence of infectious diseases such as HIV, citing a UNAIDS update from August 2022, reported approximately 38.4 million people worldwide living with HIV in 2021. This includes 36.7 million adults and 1.7 million children. The high incidence of infectious diseases is expected to drive molecular die market growth due to the increased adoption of molecular diagnostics for HIV.

Factors such as technological advancements, a growing elderly population, and increased demand for genetic testing are creating significant opportunities for market growth. Increased self-testing diagnostics and patient awareness about faster diagnostics also contribute to this growth. For example, in February 2023, Huwel Lifesciences developed a portable RT-PCR machine for testing various viruses.

North America Molecular Diagnostics Market

North America dominates the molecular diagnostics market due to its high prevalence of chronic diseases. Molecular diagnostics play an important role in the early detection, diagnosis, and monitoring of conditions like cancer and infectious diseases, leading to a shift from traditional diagnostic methods. The estimated number of new cancer cases and deaths due to cancer in the United States in 2023, as reported by the ACS 'Cancer Facts & Figures 2022'. It also suggests that the high incidence of cancer in the region is expected to drive the growth of the oncology molecular diagnostics market due to the increased adoption of molecular diagnostics for cancer diagnosis. The United States is a hub for technological innovation and research in molecular diagnostics, with many leading biotechnology and diagnostic companies driving the development and commercialization of cutting-edge molecular diagnostic technologies. The United States has one of the highest healthcare expenditures globally, facilitating the adoption of advanced diagnostic technologies, including molecular diagnostics.

Molecular Diagnostics Industry Analysis

The leading market players in the Molecular Diagnostics market are F Hoffmann-la Roche Ltd, Illumina Ltd, Hologic Corporation, Agilent Technologies Inc., Qiagen NV, Myriad Genetics, Abbott Laboratories, Biomerieux SA, Bio-Rad Laboratories Inc., and Sysmex Corporation.

Molecular Diagnostics Company News

  • In January 2024, Illumina collaborated with Janssen to develop a molecular residual disease liquid biopsy test. The company plans to create a cost-effective whole-genome sequencing multi-cancer test to detect ctDNA
  • In March 2023, Illumina Inc. and GenoScreen collaborated to offer a package that includes Illumina products and the GenoScreen Deeplex Myc-TB assay, a targeted next-generation sequencing (NGS)- based test for rapid and extensive detection of anti-TB drug resistance.
  • In March 2023, Oxford Gene Technology launched eight of its CytoCellfluorescence in situ hybridization probes, certified for clinical use by the In Vitro Diagnostics Regulation (IVDR) in Europe.
  • In August 2023, QIAGEN received the U.S. FDA approval for the Therascreen PDGFRA RGQ PCR kit. This aids physicians in identifying patients with gastrointestinal stromal tumors (GIST).
  • In January 2023, the U.S. FDA approved EUA for the VIASURE Monkeypox Virus Real-Time PCR Reagents developed by BD and CerTest Biotec to detect the Mpox virus.
  • In March 2023, Lucira Health launched the first and only at-home COVID-19 and flu tests in the U.S. The U.S. FDA gave the COVID-19 & Flu Home Test the first and only Emergency Use Authorization (EUA) for OTC usage at home and other non-laboratory locations.
  • In August 2023, Indian companies CrisprBits and MolBio Diagnostics entered a strategic collaboration to revolutionize POC diagnostics by integrating CRISPR technology into POC tests to detect pathogens and genetic markers.

Technology - Global Molecular Diagnostics Market

1. Chips and Microarrays

2. In Situ Hybridization

3. Sequencing

4. Mass Spectrometry (MS)

5. PCR

6. Other Technologies

Application - Global Molecular Diagnostics Market

1. Pharmacogenomics

2. Infectious Disease

3. Genetic Disease Screening

4. Oncology

5. Blood Screening

6. Microbiology

7. Human Leukocyte Antigen Typing

Product - Global Molecular Diagnostics Market

1. Instruments

2. Reagents

3. Other Products

End User - Global Molecular Diagnostics Market

1. Hospitals

2. Laboratories

3. Other End Users

Geography - Global Molecular Diagnostics Market

North America

1. United States

2. Canada

Europe

1. France

2. Germany

3. Italy

4. Spain

5. United Kingdom

6. Belgium

7. Netherlands

8. Turkey

Asia Pacific

1. China

2. Japan

3. India

4. Australia

5. South Korea

6. Thailand

7. Malaysia

8. Indonesia

9. New Zealand

Latin America

1. Brazil

2. Mexico

3. Argentina

Middle East & Africa

1. South Africa

2. Saudi Arabia

3. United Arab Emirates

Company Insights:

  • Overviews
  • Recent Developments & Strategies
  • Product Portfolio & Product Launch in Last 1 Year
  • Revenue

Company Analysis:

1. F Hoffmann-la Roche Ltd

2. Illumina Ltd

3. Hologic Corporation

4. Agilent Technologies Inc.

5. Qiagen NV

6. Myriad Genetics

7. Abbott Laboratories

8. Biomerieux SA

9. Bio-Rad Laboratories Inc.

10. Sysmex Corporation.

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamic

  • 4.1 Growth Drivers
  • 4.2 Challenges
  • 4.3 Opportunities

5. Global Molecular Diagnostics Market

6. Global Molecular Diagnostics Market Share Analysis

  • 6.1 By Technology
  • 6.2 By Application
  • 6.3 By Product
  • 6.4 By End User
  • 6.5 By Geography

7. Technology

  • 7.1 Chips and Microarrays
  • 7.2 In Situ Hybridization
  • 7.3 Sequencing
  • 7.4 Mass Spectrometry (MS)
  • 7.5 PCR
  • 7.6 Other Technologies

8. Application

  • 8.1 Pharmacogenomics
  • 8.2 Infectious Disease
  • 8.3 Genetic Disease Screening
  • 8.4 Oncology
  • 8.5 Blood Screening
  • 8.6 Microbiology
  • 8.7 Human Leukocyte Antigen Typing

9. Product

  • 9.1 Instruments
  • 9.2 Reagents
  • 9.3 Other Products

10. End User

  • 10.1 Hospitals
  • 10.2 Laboratories
  • 10.3 Other End Users

11. Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
  • 11.2 Europe
    • 11.2.1 France
    • 11.2.2 Germany
    • 11.2.3 Italy
    • 11.2.4 Spain
    • 11.2.5 United Kingdom
    • 11.2.6 Belgium
    • 11.2.7 Netherlands
    • 11.2.8 Turkey
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 Australia
    • 11.3.5 South Korea
    • 11.3.6 Thailand
    • 11.3.7 Malaysia
    • 11.3.8 Indonesia
    • 11.3.9 New Zealand
  • 11.4 Latin America
    • 11.4.1 Brazil
    • 11.4.2 Mexico
    • 11.4.3 Argentina
  • 11.5 Middle East & Africa
    • 11.5.1 South Africa
    • 11.5.2 Saudi Arabia
    • 11.5.3 United Arab Emirates

12. Porter's Five Forces Analysis

  • 12.1 Bargaining Power of Buyers
  • 12.2 Bargaining Power of Suppliers
  • 12.3 Degree of Competition
  • 12.4 Threat of New Entrants
  • 12.5 Threat of Substitutes

13. SWOT Analysis

  • 13.1 Strength
  • 13.2 Weakness
  • 13.3 Opportunity
  • 13.4 Threats

14. Key Players Analysis

  • 14.1 F Hoffmann-la Roche Ltd
    • 14.1.1 Overviews
    • 14.1.2 Recent Developments & Strategies
    • 14.1.3 Product Portfolio & Product Launch in Last 1 Year
    • 14.1.4 Revenue
  • 14.2 Illumina Ltd
    • 14.2.1 Overviews
    • 14.2.2 Recent Developments & Strategies
    • 14.2.3 Product Portfolio & Product Launch in Last 1 Year
    • 14.2.4 Revenue
  • 14.3 Hologic Corporation
    • 14.3.1 Overviews
    • 14.3.2 Recent Developments & Strategies
    • 14.3.3 Product Portfolio & Product Launch in Last 1 Year
    • 14.3.4 Revenue
  • 14.4 Agilent Technologies Inc.
    • 14.4.1 Overviews
    • 14.4.2 Recent Developments & Strategies
    • 14.4.3 Product Portfolio & Product Launch in Last 1 Year
    • 14.4.4 Revenue
  • 14.5 Qiagen NV
    • 14.5.1 Overviews
    • 14.5.2 Recent Developments & Strategies
    • 14.5.3 Product Portfolio & Product Launch in Last 1 Year
    • 14.5.4 Revenue
  • 14.6 Myriad Genetics
    • 14.6.1 Overviews
    • 14.6.2 Recent Developments & Strategies
    • 14.6.3 Product Portfolio & Product Launch in Last 1 Year
    • 14.6.4 Revenue
  • 14.7 Abbott Laboratories
    • 14.7.1 Overviews
    • 14.7.2 Recent Developments & Strategies
    • 14.7.3 Product Portfolio & Product Launch in Last 1 Year
    • 14.7.4 Revenue
  • 14.8 Biomerieux SA
    • 14.8.1 Overviews
    • 14.8.2 Recent Developments & Strategies
    • 14.8.3 Product Portfolio & Product Launch in Last 1 Year
    • 14.8.4 Revenue
  • 14.9 Bio-Rad Laboratories Inc.
    • 14.9.1 Overviews
    • 14.9.2 Recent Developments & Strategies
    • 14.9.3 Product Portfolio & Product Launch in Last 1 Year
    • 14.9.4 Revenue
  • 14.10 Sysmex Corporation
    • 14.10.1 Overviews
    • 14.10.2 Recent Developments & Strategies
    • 14.10.3 Product Portfolio & Product Launch in Last 1 Year
    • 14.10.4 Revenue
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!